Detailed explanation of the efficacy and role of dabrafenib/dabrafenib

Dabrafenib is a competitive and selective BRAF inhibitor by binding to its ATP pocket. Although dabrafenib inhibits wild-type BRAF, it has higher affinity for mutant forms of BRAF, including BRAF V600E, BRAF V600K, and BRAF V600D. BRAF is a serine/threonine protein kinase involved in activating the RAS/RAF/MEK/ERK or MAPK pathway, which is involved in cell cycle progression, cell proliferation and prevention of apoptosis. Accordingly, constitutively active mutations of BRAF, such as BRAF V600E, are frequently observed in many types of cancer, including melanoma, lung and colon cancer.

Dabrafenibis a kinase inhibitor primarily used to target theBRAF V600E mutation in multiple types of cancer. Although both dabrafenib and trametinib inhibit the RAS/RAF/MEK/ERK pathway, they inhibit different effectors of this pathway, thereby increasing response rates and mitigating resistance without cumulative toxicity.

The approval of trametinib for the treatment of melanoma is based on the results ofCOMBI-AD, a Phase III study involving 870 patients with BRAF V600E/K mutation-positive stage III melanoma who received dabrafenib + trametinib after complete surgical resection. Patients received dabrafenib (150 mg BID) + trametinib (2 mg QD) (n=438) or matching placebo (n=432). After a median follow-up of 2.8 years, the primary endpoint of recurrence-free survival (RFS) was achieved.

As far as thyroid cancer is concerned, dabrafenib combined with trametinib is the first regimen proven to have effective clinical activity against BRAF V600E mutated anaplastic thyroid cancer and is well tolerated. These findings represent meaningful therapeutic advances for this rare disease.